Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 10/20 | 0.55 |
| ▸ | TP53 | P04637 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | SPR | P35270 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3939347 | 0.89 | HSD11B1 (0.55) | HSD11B1MAPTTP53LMNASPR | |
| SCHEMBL1858381 | 0.87 | HSD11B1 (0.70) | HSD11B1MAPTTP53LMNASPR | |
| SCHEMBL3935898 | 0.87 | MAPT (0.59) | HSD11B1MAPTTP53LMNAGAA | |
| SCHEMBL1857708 | 0.87 | HSD11B1 (0.53) | HSD11B1MAPTTP53LMNASPR | |
| SCHEMBL3937707 | 0.87 | HSD11B1 (0.54) | HSD11B1MAPTTP53SPR | |
| Hydrochloric Acid SCHEMBL1857438 | 0.86 | HSD11B1 (0.69) | HSD11B1MAPTTP53LMNASPR | |
| SCHEMBL3929608 | 0.86 | HSD11B1 (0.54) | HSD11B1MAPTTP53LMNASPR | |
| Hydrochloric Acid SCHEMBL1856746 | 0.86 | HSD11B1 (0.52) | HSD11B1MAPTTP53LMNASPR | |
| SCHEMBL1855963 | 0.85 | HSD11B1 (0.54) | HSD11B1MAPTTP53LMNASPR | |
| SCHEMBL3931229 | 0.84 | MAPT (0.55) | HSD11B1MAPTTP53LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947834-B2 | Substituted quinoxalines, their preparation and their therapeutical use as 11βHSD1 modulators | SANOFI-AVENTIS (FR) | 2011-05-24 | — | — | US | disclosed |
| US-20090176775-A1 | DERIVATIVES OF UREAS OF PIPERIDINE OR PYRROLIDINE, THEIR PREPARATION AND THEIR THERAPEUTICAL USE | SANOFI-AVENTIS (FR) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176775-A1 | DERIVATIVES OF UREAS OF PIPERIDINE OR PYRROLIDINE, THEIR PREPARATION AND THEIR THERAPEUTICAL USE | HSD11B1, HSD3B1, ADH1C | HSD11B1 1/4885MAPT 1529/4885TP53 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.